相关临床试验
28
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1815
已完成
18
64.3%
尚未招募
2
7.1%
招募中
3
10.7%
Unknown
5
17.9%
暂无批准数据
- A 47-year-old woman with three life-threatening autoimmune diseases achieved complete treatment-free remission after receiving CAR-T cell therapy at University Hospital Erlangen in Germany. - The therapy successfully targeted rogue B-cells causing autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome, marking the first reported case of simultaneous treatment of multiple autoimmune conditions. - Within weeks of treatment, the patient no longer required daily blood transfusions and has maintained remission for over 14 months, demonstrating the potential for CAR-T therapy to reset dysfunctional immune systems. - Researchers believe early intervention with CAR-T therapy could prevent organ damage and complications from years of ineffective conventional treatments in severe autoimmune disease patients.
- A 47-year-old woman with three concurrent autoimmune diseases achieved complete symptom resolution after receiving a single dose of CAR-T cell therapy at University Hospital Erlangen in Germany. - The patient had autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome, requiring daily blood transfusions and failing nine previous treatments. - Within seven days of CAR-T treatment, the bedridden patient was mobile, and after 11 months remains medication-free with normal blood parameters. - This represents the first successful treatment of three simultaneous autoimmune conditions with a single CAR-T therapy, demonstrating the potential for this approach across multiple autoimmune diseases.
- Quell Therapeutics has initiated the CHILL phase 1/2 trial of QEL-005, an autologous CAR-Treg therapy targeting rheumatoid arthritis and systemic sclerosis across the UK, Germany, and Spain. - The therapy uses a CD19-directed CAR to restore immune balance by regulating rather than depleting immune cells, distinguishing it from traditional CAR-T therapies that "kill" pathogenic cells. - Early results are expected in early 2027, with the company positioning QEL-005 as a potential "pipeline-in-a-product" for complex autoimmune diseases. - The advancement follows Quell's decision to pause development of its liver transplant program QEL-001 to focus internal resources on autoimmune applications.
- Berlin Cures' Phase 2 trial of BC 007 (rovunaptabin) for long COVID failed in November 2024 due to poor patient selection and inadequate outcome measures, despite some participants experiencing dramatic symptom improvements. - A separate smaller trial at University Hospital Erlangen found significant improvements in fatigue and post-exertional malaise using more targeted selection criteria and validated ME assessment tools. - Former Berlin Cures CEO Oliver von Stein has launched APTA Therapeutics to acquire the drug's assets and plans new studies within 18 months, focusing on better patient stratification and collaboration with long COVID experts.
